We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Calls into Question Inconsistent Benefit for BioMarin’s DMD Candidate
FDA Calls into Question Inconsistent Benefit for BioMarin’s DMD Candidate
Spotty, inconclusive data and potentially skewed, biased findings have raised FDA concerns about the efficacy of BioMarin Pharmaceutical’s Duchenne muscular dystrophy candidate drisapersen, which is scheduled to go before members of an agency advisory panel tomorrow.